The U.S. Government Is Investing $2 Billion in the Quantum Computing Space, But Did It Miss the Best Stock to Buy?

The U.S. government plans to provide over $2 billion in incentives and investments to quantum computing companies under the CHIPS and Science Act, including $1 billion each for IBM's Anderon and the government-backed expansion of domestic quantum manufacturing. GlobalFoundries is set to receive $375 million and a roughly 1% Commerce Department equity stake, while seven other quantum names including Rigetti, D-Wave Quantum, and Infleqtion also get support. The article is bullish on IonQ, arguing its pending SkyWater acquisition could make it the only vertically integrated quantum computing company and highlighting its 99.99% two-qubit gate fidelity record.

Analysis

The market is likely to misread this as a simple subsidy grab, but the more important effect is industrial validation: federal capital lowers the cost of customer acquisition for the entire quantum stack and can compress financing risk premia for the next 12-24 months. That said, the government’s preference for manufacturing-centric awards creates a bifurcation between companies that can monetize hardware today versus those still selling a long-duration R&D narrative. The immediate beneficiaries are the names with credible fab/manufacturing adjacency and procurement leverage; the weakest are pure software stories that need a broader commercialization cycle to justify valuation.

IonQ’s omission is a near-term relative catalyst rather than a fundamental indictment. If the SkyWater transaction closes and integration looks clean, the market will likely re-rate IonQ as the only vertically integrated platform with a path to better gross margin control and faster iteration cycles, but that thesis needs proof over the next 2-3 quarters, not years. The bigger second-order opportunity may sit in suppliers and enablers: domestic foundry expansion tends to create a longer tail of equipment, materials, test, and advanced packaging demand that is less headline-sensitive than the quantum names themselves.

The main risk is that the current enthusiasm front-loads multiple expansion before technical milestones are commercially useful. Quantum fidelity and error-correction progress are real, but the market routinely prices 3-5 years of adoption into stocks that still have limited revenue durability; any delay in funding disbursement, equity-stake negotiations, or integration execution could trigger a sharp reset. A reversal is also possible if Washington broadens awards to additional incumbents or if the IonQ acquisition raises antitrust/closing friction, which would dilute the perceived scarcity value of the current winners.

Consensus is probably underestimating how differentiated the regulatory outcome is between "awarded capital" and "able to turn capital into manufacturing throughput." That distinction favors IBM and GFS more than the pure plays in the near term, while IonQ remains the highest-upside option if it converts vertical integration into repeatable process advantage. The setup argues for owning the names with real balance sheet support and using the more promotional names as tactical trades rather than core positions.

Key Decisions for Investors

• Long IBM vs. long-only basket: prefer IBM over the pure-play quantum names for the next 6-12 months; it has the cleanest federal de-risking plus the lowest execution risk. Use as a defensive way to express quantum exposure with better downside support.
• Pair trade: long IONQ / short QBTS into the next 1-2 quarters. IonQ has the clearest path to vertical integration and technical differentiation; QBTS is more dependent on narrative re-rating and is more vulnerable if capital rotates toward awarded incumbents.
• Buy GFS on pullbacks over the next 4-8 weeks if the equity-stake process is orderly. The asymmetry is favorable: the government imprimatur can expand its strategic moat even if near-term revenue contribution is small.
• Speculative catalyst trade: buy IONQ call spreads 3-6 months out around acquisition-close timing. Risk/reward is attractive if integration news validates the "only vertically integrated" thesis, but size small because any delay could compress the premium quickly.
• Avoid chasing the first 1-2 session move in the smaller quantum names; wait for a 10-15% retracement or a financing/integration update before adding. These names are likely to mean-revert unless they convert policy headlines into booked orders.